Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are male and older than 18 years of age
- You are able to carry out basic daily activities with minimal or no limitations (confirm with trial site regarding activity level assessment)
- You have been diagnosed with prostate cancer that has spread to other parts of the body and is no longer responding to hormone-lowering treatments, confirmed by a tissue sample (biopsy or removed prostate tissue)
- You have previously been treated with at least one chemotherapy regimen containing taxane drugs, and at least one newer type of hormone therapy
- You are currently receiving treatment to lower testosterone levels, with very low testosterone in your blood, or you have had surgical removal of the testicles
- Your prostate cancer is getting worse, shown by rising PSA blood test levels over time, new or growing tumours on scans, or new spots appearing on bone scans
- You have at least one area where cancer has spread (to bones, lymph nodes, or organs), confirmed by scans taken within the last 43 days before joining the trial
- A special scan called a PSMA PET scan confirms that your cancer is suitable for a type of treatment that targets the PSMA protein on cancer cells
- Your blood counts, liver, and kidneys are working well enough to safely participate (confirm specific levels with trial site)
- You are able to give your free and informed agreement to take part in the trial
- You are covered by a social security or health insurance scheme (confirm with trial site, as this may be specific to the country where the trial is running)
Who may not be able to join:
- You are currently still taking a newer type of hormone therapy drug
- You have had another type of cancer in the past 3 years that could affect your life expectancy or make it hard to assess your prostate cancer
- You are a legally protected adult (confirm with trial site)
- You have a physical or mental health condition that could interfere with the study's goals or assessments
- You are unable to understand or follow the study's instructions and requirements
- Your general health and ability to do daily activities is significantly limited (confirm with trial site regarding activity level assessment)
- You have a blockage or swelling in the tubes connecting your kidneys to your bladder that has not been treated
- You have a blocked bladder outlet or uncontrollable urinary leakage at the same time
- You have symptoms of pressure on your spinal cord, or scans suggest this could happen soon
- You have bones at high risk of breaking due to your cancer
- You have active and symptomatic cancer that has spread to the brain
- You are currently taking part in another clinical trial, or have taken an experimental treatment within 28 days before joining this trial
- The only tissue sample available for your prostate cancer diagnosis comes from a spread (metastatic) site rather than the prostate itself
- You have received certain types of bone-targeting radiation treatments (such as Radium-223 or similar) within the 6 months before joining the trial
- You have previously been treated with any radioactive drug that targets the PSMA protein
- You have a known allergy or sensitivity to any of the treatments used in this trial or similar drugs
- You have recently had a blood transfusion or received bone marrow stimulating injections specifically to meet the blood count requirements for this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0473278005
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Molecular abnormalities retained on primary tumor sample predicting response to Lu-PSMA in metastatic castration resistant prostate cancer patients assessed according to RECIST 1.1 and/or PCWG3 criteria
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.